EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Assessing tumor heterogeneity and FLOT/FOLFOX-induced alterations in cancer stem cells and cancer immune checkpoint molecules using patient-derived tumor organoids

Chih-Cheng Cheng, Bor-Chyuan Su iD, Wei-Yu Chen, Hsin-Hsien Yu

International Journal of Immunopathology and Pharmacology · 2026-07 · 40

DOI: 10.1177/03946320261474427 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Immunopathology and Pharmacology, online erschienen am 31.07.2026. Verfasst von Chih-Cheng Cheng und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of General Surgery, Department of Surgery, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan. Hauptthemen laut MEDLINE: Neoplastic Stem Cells, Organoids, Antineoplastic Combined Chemotherapy Protocols, Stomach Neoplasms. Die Arbeit nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Higher Education Sprout Project by the Ministry of Education (MOE) in Taiwan, The National Science and Technology Council, Taipei Medical University–Wan Fang Hospital.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Gastric cancer is a deadly disease with poor prognosis and unfavorable therapeutic outcomes. It is known that a major cause of treatment failure for gastric cancer is related to tumor heterogeneity. However, it is difficult to assess heterogeneity, as the composition of tumors is dynamic and cancer treatments reshape cell diversity and gene/protein expression profiles.

Objective

We utilized gastric cancer patient-derived tumor organoids to monitor tumor heterogeneity and the impacts of chemotherapy (FLOT and FOLFOX) on cancer stem cells (LGR5 and CD133) and cancer immune checkpoint molecules (MHC-I and PD-L1).

Methods

Six tumor organoids were established from different patients or different regions of the same tumor. The tumor organoids were used to investigate the real-time profiles of cancer stem cell marker expression and cancer immune checkpoint molecule expression after chemotherapy treatment. Tumor suppression was monitored by the propidium iodide assay and measurements of tumor organoid diameter. Expression levels of cancer stem cell markers and immune checkpoint molecules were analyzed by flow cytometry.

Results

Growth of all tumor organoids could be suppressed by chemotherapy. However, diverse impacts of FLOT and FOLFOX were observed in terms of the expression profiles of cancer stem cell markers and cancer immune checkpoint molecules. In particular, tumor organoids from different patients exhibited distinct expression profiles for cancer stem cell markers and immune checkpoint molecules after treatment with the same chemotherapeutic regimen. Similar observations were made with tumor organoids derived the same patient but different tumor regions.

Conclusion

Our findings demonstrated that spatial and temporal tumoral heterogeneity can be observed after treatment with chemotherapy, suggesting that repeated monitoring of tumor characteristics may be essential for clinical decision making. In addition, sampling of multiple sites at multiple time-points might be important when evaluating the impacts of chemotherapy on cancer stem cells markers and immune checkpoint molecules.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neoplastic Stem CellsOrganoidsAntineoplastic Combined Chemotherapy ProtocolsStomach NeoplasmsHumansFluorouracilOrganoplatinum CompoundsLeucovorinBiomarkers, TumorImmune Checkpoint Inhibitors

Stichwörter der Autor:innen

cancer immune checkpoint moleculescancer organoidcancer stem cellschemotherapy responseintertumoral heterogeneityintratumoral heterogeneity

Substanzen

FluorouracilOrganoplatinum CompoundsLeucovorinBiomarkers, TumorImmune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Division of General Surgery, Department of Surgery, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan.
  • Department of Anatomy and Cell Biology, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan.
  • Department of Pathology, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan.
  • Department of Pathology, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan.
  • Division of General Surgery, Department of Surgery, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan.

ORCID-Profile: Bor-Chyuan Su

Förderung

  • Higher Education Sprout Project by the Ministry of Education (MOE) in Taiwan
  • The National Science and Technology Council
  • Taipei Medical University–Wan Fang Hospital

Zitieren

APA

Cheng, C. C., Su, B. C., Chen, W. Y., & Yu, H. H. (2026). Assessing tumor heterogeneity and FLOT/FOLFOX-induced alterations in cancer stem cells and cancer immune checkpoint molecules using patient-derived tumor organoids. International Journal of Immunopathology and Pharmacology, 40. https://doi.org/10.1177/03946320261474427

Vancouver

Cheng CC, Su BC, Chen WY, Yu HH. Assessing tumor heterogeneity and FLOT/FOLFOX-induced alterations in cancer stem cells and cancer immune checkpoint molecules using patient-derived tumor organoids. International Journal of Immunopathology and Pharmacology. 2026;40. doi:10.1177/03946320261474427

BibTeX
@article{Cheng2026,
  author = {Cheng, Chih-Cheng and Su, Bor-Chyuan and Chen, Wei-Yu and Yu, Hsin-Hsien},
  title = {Assessing tumor heterogeneity and FLOT/FOLFOX-induced alterations in cancer stem cells and cancer immune checkpoint molecules using patient-derived tumor organoids},
  journal = {International Journal of Immunopathology and Pharmacology},
  year = {2026},
  volume = {40},
  doi = {10.1177/03946320261474427}
}
Kostenlos starten →